A practical reference on obesity research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-23 and is reviewed periodically as new material appears.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
== Functions == After water, proteins account for more mass in an organism than any other type of molecule. Protein is present in every cell, and it is a structural component of every body tissue and organ, including hair, skin, blood, and bone. Protein is especially abundant in muscle. Cellular messengers (hormones) and transport molecules are constructed from proteins, including enzymes and antibodies, as are cell membrane components, such as glycoproteins, G proteins, and ion channels. The types of amino acids and their sequence determine the unique 3-dimensional structure and function of a protein. Amino acids obtained through protein catabolism also enable the biosynthesis of non-protein molecules that are essential for life, such as nucleotides, certain neurotransmitters, and heme.
as follows. They are calculated for the Gaussian distribution of asperities, which have been shown to be unrealistic for engineering surface but can be assumed where friction, load carrying capacity or real contact area results are not critical to the analysis.
=== Lifespan === In the East China Sea, blue mackerel spawn between February and May, when the water temperatures are ideal. In New South Wales, most spawning occurs 10 km (6.2 mi) offshore in waters 100–125 m (328–410 ft) in depth. The East Australian Current can carry eggs and larvae away from the original spawning grounds, broadening the area in which blue mackerel are located. However, egg and larvae probability of surviving decreases the further they are carried by the current. A mature blue mackerel is considered to be over 31 cm (12 in) long. Mackerel can live up to 7 years and grow up to 50 cm (20 in) in length, but are most commonly found to be between 1 and 3 years of age. Counting the marks on otoliths is used to determine the age of blue mackerel.
=== Industry === Formaldehyde is produced industrially by the catalytic oxidation of methanol. The most common catalysts are silver metal (i.e. the FASIL process), iron(III) oxide, iron molybdenum oxides (e.g. iron(III) molybdate) with a molybdenum-enriched surface, or vanadium oxides. In the commonly used formox process, methanol and oxygen react at c. 250–400 °C in presence of iron oxide in combination with molybdenum or vanadium to produce formaldehyde according to the chemical equation
==== Prostate cancer ==== A 2016 review concluded that "current evidence from observational studies and small clinical trials is not robust enough to understand whether soy protein or isoflavone supplements may help prevent or inhibit the progression of prostate cancer." A 2010 review showed that neither soy foods nor isoflavone supplements alter measures of bioavailable testosterone or estrogen concentrations in men. Soy consumption has been shown to have no effect on the levels and quality of sperm. Meta-analyses on the association between soy consumption and prostate cancer risk in men concluded that dietary soy may lower the risk of prostate cancer.
Sources: en.wikipedia.org
autoignition temperature Also kindling point. The lowest temperature at which a given substance will spontaneously ignite in a normal atmosphere without an external source of ignition such as a flame or spark, i.e. when the ambient temperature is sufficiently high to provide the activation energy needed for combustion. Substances which spontaneously ignite at naturally occurring temperatures are termed pyrophoric. Compare ignition temperature.
Chaplain, University of Sunderland. For services to Higher Education. Dr Catherine Marian Hubbert. Macmillan General Practitioner and Founder, Woodlands Hospice Charitable Trust. For services to Palliative Care. Antony Jasper Hudgell. Co-Founder, Tony Hudgell Foundation. For services to the Prevention of Child Abuse. Karen Humphries. Assessor and Duke of Edinburgh Award Manager, Nunnery Wood High School, Worcester. For services to Young People. Graham Walter Hundley. Emergency Response Volunteer, Cumbria. For voluntary service to the British Red Cross. Elaine Hutchings. For services to the community in Lichfield, Staffordshire during Covid-19. Lena Moira Hutchinson. For voluntary services to the community in Larne, County Antrim. William David Hutton. Founder, Campsie Accordion and Fiddle Club. For services to Music and to the community in Dunbartonshire. Robert Alan John Illman. For services to Mountain Rescue in Dartmoor, Devon. Richard Stansfield Isaac. Community and Sustainability Manager, Northern Trains. For services to Inclusion in the Rail Industry. Clive Herbert Jackson. For services to the community in York. Christopher Angus Jamieson. Special Inspector, British Transport Police (Scotland). For services to Policing. Patricia Carol Jarman. For services to the community in Stalybridge, Metropolitan Borough of Tameside. Michael George Jaynes. Akela, 1st Hatherley Scouts, Cheltenham. For services to Young People and to the community in Cheltenham, Gloucestershire. Hilary Mary Jenkins. For services to the community in Wiltshire, particularly during Covid-19.
== Instruments and Technologies == The National Dope Testing Laboratory is equipped with state of the art technologies and the most modern equipment. The use of Gas Chromatography coupled with Mass Spectrometry (GC-MS) is the most common and the oldest technology being used worldwide for dope testing. Nowadays, the use of liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) has become quite widespread. This technique has helped detect the difficult drugs falling into various categories of banned substances and is becoming increasingly more important in the fight against doping. Apart from GC-MS and LC-MS/MS, the use of Gas Chromatography coupled with tandem Mass Spectrometry (GC-MS/MS) and Isotope-ratio mass spectrometry (IRMS) is also very prevalent in sports dope testing. Both GC-MS/MS and LC-MS/MS are used primarily to analyze urine samples. The analysis of the blood matrix requires a completely different type of equipment which is commonly used in hospital laboratories.
== Prize money == The funding structure consists of non-dilutive cash grants distributed to the top three finalists across each of the 9 regional categories and 1 thematic award, comprising a total cohort of 30 fellows annually. Financial rewards are categorized by final placement within each category, amounting to a total of 1.9 million USD.
Sources: en.wikipedia.org
=== Manufacturing === Vanillin has been used as a chemical intermediate in the production of pharmaceuticals, cosmetics, and other fine chemicals. In 1970, more than half the world's vanillin production was used in the synthesis of other chemicals. Vanillin may be used to manufacture bioplastics. As of 2016, vanillin uses have expanded to include perfumes, flavoring and aromatic masking in medicines, various consumer and cleaning products, and livestock foods.
=== Etymology === Lactobacillic acid and Lactobacillussäure are translations of the English term 'lactobacillic acid', which scientists proposed when this fatty acid was discovered (1950) in a Lactobacillus species. In the German-language literature, the term lactobacillic acid is used more frequently than lactobacillus acid. As early as 1938, another group of researchers discovered an unusual fatty acid from the bacterium Agrobacterium tumefaciens (at that time called Bacterium tumefaciens or Phytomonas tumefaciens) was isolated and after the generic name as phytomonic acid. According to the knowledge of scientists at the time, this saturated fatty acid had the molecular formula C20H40O2. The proposed structure was a branched-chain fatty acid with a methyl group as a branch, methylnonadecanoic acid. However, K. Homann et al. were able to show in 1955 that this compound isolated from P. tumefaciens was in fact lactobacillic acid. According to them, the substance originally investigated had been contaminated.
== Notable people == Eric Decker, National Football League player Alvin Ganzer (1911–2009), film director, born in Cold Spring John J. Kinzer (1891–1986), Minnesota state legislator and farmer Doug Stang, Minnesota state legislator Justin Stommes, professional basketball player; graduated from Rocori High School
It has also been reported as a folk remedy for diabetes: since inulin is not assimilated in the intestine, it does not cause a glycemic spike as potatoes would. Temperature variances have been shown to affect the amount of inulin the Jerusalem artichoke can produce. It makes less inulin in a colder region than when it is in a warmer region.
=== Factors that lower survival === Much of prognosis can be determined from the damage due to primary cancer. Negative hormone receptor status, poor performance status, more than 3 chemotherapy regimes, and high Cyfra 21-1 level at diagnosis, all indicates lower survival period of patients with NM. Cyfra 21-1 is a fragment of the cytokeratin 19 and may reflect the tumor burden within the CSF.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.